BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17524265)

  • 1. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
    Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
    Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
    Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
    Liang J; Han T; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
    Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
    Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
    Xu Y; Wang JB; Ji SW; Zhang YG; Siqingtu NL; Zhao P; Guo HH; Li Y; Jiao J; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):259-62. PubMed ID: 20460043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Lai CL; Leung N; Teo EK; Tong M; Wong F; Hann HW; Han S; Poynard T; Myers M; Chao G; Lloyd D; Brown NA;
    Gastroenterology; 2005 Aug; 129(2):528-36. PubMed ID: 16083710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
    Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telbivudine.
    Keam SJ
    Drugs; 2007; 67(13):1917-29. PubMed ID: 17722961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
    Chan HL; Chen YC; Gane EJ; Sarin SK; Suh DJ; Piratvisuth T; Prabhakar B; Hwang SG; Choudhuri G; Safadi R; Tanwandee T; Chutaputti A; Yurdaydin C; Bao W; Avila C; Trylesinski A
    J Viral Hepat; 2012 Oct; 19(10):732-43. PubMed ID: 22967105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
    Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
    J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telbivudine for the management of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.